Table 1 Patient characteristics of reports on vaccine-associated renal adverse reaction.
From: Global burden of vaccine-associated kidney injury using an international pharmacovigilance database
AKI (n = 5901) | GN (n = 3312) | TIN (n = 374) | |
|---|---|---|---|
Age, yr | |||
0–1 | 99 (1.7) | 91 (2.8) | 8 (2.1) |
2–11 | 33 (0.6) | 317 (9.6) | 4 (1.1) |
12–17 | 105 (1.8) | 226 (6.8) | 39 (10.4) |
18–64 | 1767 (29.9) | 1335 (40.3) | 181 (48.4) |
≥65 | 3092 (52.4) | 566 (17.1) | 54 (14.4) |
Unknown | 805 (13.6) | 777 (23.5) | 88 (23.5) |
Sex | |||
Female | 2566 (43.5) | 1634 (49.8) | 196 (52.6) |
Unknown | 19 (0.3) | 28 (0.7) | 1 (0.3) |
Study-relation | |||
Study related | 48 (0.8) | 46 (1.4) | 2 (0.5) |
Non-study related | 5852 (99.2) | 3263 (98.5) | 372 (99.5) |
Unknown | 1 (0.0) | 3 (0.1) | 0 (0.0) |
Median (IQR) time-to-onset, d | 3.9 (3.1–4.7) | 9.5 (7.2–11.8) | 9.1 (4.5–13.8) |
Fatal outcomes | |||
Non-serious | 1427 (24.2) | 797 (24.1) | 149 (39.8) |
Serious | 821 (13.9) | 958 (28.9) | 77 (20.6) |
Unknown | 3653 (61.9) | 1557 (47.0) | 148 (39.6) |
Single drug suspected | 5876 (99.6) | 3312 (100.0) | 374 (100.0) |
